Haohai Biotec (06826) Sets 20 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal
Bulletin Express
Mar 10
Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotec, stock code: 06826) has announced that its board of directors will convene on 20 March 2026 in Shanghai. The meeting’s agenda includes approval and publication of the consolidated annual results for the financial year ended 31 December 2025, as well as consideration of a final dividend recommendation.
The board currently comprises four executive directors (Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi, Mr. Tang Minjie), three non-executive directors (Ms. You Jie, Mr. Huang Ming, Mr. Wei Changzheng) and four independent non-executive directors (Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe). The meeting will be chaired by Dr. Hou Yongtai.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.